news
Tract Bio identifies drug targets for oesophageal cancer
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
List view / Grid view
Drug Target Review
news
Novel radioactive drug targets aggressive metastatic melanoma
Scientists in Japan have developed a new radioactive drug that emits alpha particles, showing promise for targeting metastatic melanoma - an aggressive skin cancer resistant to many conventional treatments.
news
New research offers hope for high-grade glioma treatment
High-grade glioma, an aggressive brain cancer affecting both paediatric and adult patients, remains difficult to treat. A collaborative study from the University of Michigan, Dana-Farber Cancer Institute, and the Medical University of Vienna reveals a promising new treatment approach.
whitepaper
Beyond the Lab: Artificial Intelligence
Download our latest report to discover how AI is transforming drug discovery, accelerating treatments and driving personalised care.
news
CeSPIACE: New peptide drug blocks COVID-19 variants
Scientists have developed CeSPIACE, a peptide drug that offers broad protection against COVID-19 variants, including Omicron XBB.1.5. Find out how it targets a stable part of the virus’s spike protein, making it resistant to mutations.
article
Abelacimab: the next frontier in safer anticoagulation therapy
Abelacimab represents a breakthrough in drug discovery, offering a novel approach to anticoagulation that could potentially prevent strokes with minimal bleeding risk. Learn how this innovative treatment could set new standards for both clinical practice and pharmaceutical research.
news
FairJourney Biologics acquires Charles River’s South San Francisco facility
FairJourney Biologics S.A., a global leader in antibody discovery and optimisation, has announced its acquisition of Charles River Laboratories’ South San Francisco site.
news
Beckman Coulter Life Sciences and Rarity Bioscience partner to advance oncology research
Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, has partnered with Rarity Bioscience to introduce a groundbreaking approach to oncology research.
news
Scientists discover key to long COVID lung damage and potential treatment
Scientists at the University of Virginia (UVA) School of Medicine have uncovered a crucial mechanism behind the lingering effects of long COVID, revealing how severe COVID-19 infections impair immune cells’ ability to repair lung tissue.
article
The future of mental health treatment: Zelquistinel’s role
Learn about zelquistinel, an innovative NMDA receptor modulator that is transforming treatment possibilities through a novel approach to synaptic plasticity. This breakthrough drug offers new insights into early drug discovery and the future of neuropsychiatric treatment.
news
First AI-designed drug, Rentosertib, officially named by USAN
Insilico Medicine’s AI-designed drug for idiopathic pulmonary fibrosis (IPF), Rentosertib, has been granted an official name by USAN. This is the first drug where both the target and compound were discovered using generative AI, marking a major milestone in AI-driven drug development.
news
Scientists turn superbug MRSA into treatable infection
Researchers have discovered a breakthrough method to silence MRSA's drug resistance, restoring its sensitivity to standard antibiotics and offering new hope in the fight against superbugs.
article
New insights into surfactant spread for lung drug delivery
A recent study led by Dr Richard McNair highlights the role of the Marangoni effect in surfactant spreading, offering potential improvements in drug development and delivery for lung diseases.
news
AWS and ElevateBio join forces to advance gene editing
ElevateBio is teaming up with Amazon Web Services (AWS) to advance CRISPR gene editing using AI and cloud computing. This collaboration aims to accelerate drug discovery for genetic diseases, making next-generation therapies more efficient and accessible.
news
Bacterial ‘jumping genes’ found to control chromosome ends
Cornell researchers have discovered how transposons, or 'jumping genes,' insert themselves into bacterial chromosome ends, potentially transforming genetic engineering and advancing biotechnology. This breakthrough could reshape antibiotic research and unlock new drug discoveries.
